Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia Developed plans for TRANQUILITY In-Care Phase 3 trial of BXCL501 for agitation associated with Alzheimer’s dementia Enhanced operational and financial flexibility through existing credit amendment Strengthened strategic leadership with recent Board appointments NEW HAVEN, Conn., Feb. 05, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTA ...

Multiple Spot Agreements Signed with Major Organizations S&P Global Platts Publishes Weekly Pricing Based on Plug Plant Production SLINGERLANDS, N.Y., Feb. 05, 2025 (GLOBE NEWSWIRE) -- In a significant move towards a more flexible and dynamic green hydrogen market, Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, has introduced the first-ever spot pricing program for liquid green hydrogen, marking a major step forward in the industry. Hydrog ...

Richard Drexler Departs from BoardTROY, Mich., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of branded innovative solutions for the cannabis and hemp industries, today announced that Peter Shapiro and Sanjay Tolia have been appointed to its Board of Directors, effective January 31, 2025. The Company also announced Richard Drexler’s departure from the Board, also effective January 31, 2025. “We are excited to welcome Peter and Sanjay to ...

- Primary endpoint achieved by both DURAVYU doses (1.34mg and 2.7mg) with extended time to first supplemental injection versus aflibercept control – - DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a 24-week gain of +7.1 letters and anatomical improvement of 76 microns reduction in CST paired with reduction in treatment burden of two-thirds – Favorable safety profile continues with no DURAVYU-related ocular or systemic SAEs – – Phase 3 non-inferiority pivotal program initiation a ...

Dayforce® recurring revenue of $347.9 million, up 19% year-over-year in the fourth quarter Total revenue of $465.2 million, up 16% year-over-year in the fourth quarter Full year 2024 net cash provided by operating activities of $281.1 million, up 28% Annual Dayforce gross revenue retention rate of 98% MINNEAPOLIS and TORONTO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Dayforce, Inc. ("Dayforce" or the "Company") (NYSE:DAY) (TSX:DAY), a global leader in human capital management ("HCM") technology, today announced its ...

Eyenovia plans to submit for U.S. device regulatory approval in Q4 of this year, marking a key step toward commercializationNEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announces recent progress on the development of its user-filled spray dispenser. “Millions of consumers have difficulty with traditional eye drops, including difficulty with ...

BOSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Plymouth Industrial REIT, Inc. (NYSE: PLYM) announced the sale of a 33,688-square-foot flex building in Memphis, TN to an end user at a price of $2.4 million. The building was part of a portfolio Plymouth acquired in July 2024 for $100.5 million. At the time of acquisition, Plymouth targeted this building for divesture as it represented a non-core asset leased on a short-term basis to a tenant known to be vacating at its scheduled lease expiration in December 2024. ...

Ramat Gan, Israel, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it will present at the BIO CEO & Investor Conference, taking place February 10-11, 2025, in New York City. Presentation Details: Event: BIO CEO & Investor Conference 2025Date & Time: February 10, 2025, at 3:45 pm ESTLocation: New York Marriott Ma ...

JetBlue to Serve Montauk Brewing's Surf Beer Golden Ale on All Domestic and International FlightsNEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Montauk Brewing Company (“Montauk Brewing” or “Montauk”), a beloved and rapidly growing craft brewer renowned for its exceptional craft beers, and a Tilray Brands, Inc. company (NASDAQ: TLRY and TSX: TLRY), today announced that The Surf Beer Golden Ale is now available for JetBlue customers on all domestic and international flights starting this month. As the first air ...

CHATHAM, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at the BIO CEO & Investor Conference on February 10, 2025, at 1:45 p.m. ET in New York City. Investors interested in arranging a meeting with the Company’s management during th ...